摘要
在美国吗,肺癌导致死亡的主要原因,非小细胞肺癌是其最常见的类型。在过去的几十年中,手术和全身治疗非小细胞肺癌取得了巨大进展,但晚期疾病的预后仍然较差。然而,治疗非小细胞肺癌新的研究是探索使用靶向治疗。间变性淋巴瘤激酶(ALK)参与正常哺乳动物中枢神经系统发育。一种涉及ALK的融合基因以及棘皮动物微管相关蛋白4(EML4)基因与5%的NSCLCs有关,并与其他致癌基因相互排斥。抗ALK靶向治疗重排是一种相对较新的治疗方式,其旨在改善晚期癌症患者的预后。两类药物Crizotinib 和 Ceritinib已经得到了FDA的批准。以及许多其他ALK抑制剂目前正处于临床试验研究阶段。本文对ALK抑制剂治疗NSCLCs进行了总结,并对将来的研究方向和挑战提出了看法。
关键词: 间变性,抑制剂,蛋白激酶,淋巴瘤,非小细胞肺癌(NSCLC)
图形摘要
Current Drug Targets
Title:Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Volume: 17 Issue: 6
Author(s): David M. Straughan, Sad C. Azoury and Vivek Shukla
Affiliation:
关键词: 间变性,抑制剂,蛋白激酶,淋巴瘤,非小细胞肺癌(NSCLC)
摘要: Lung cancer is the leading cause of cancer death among both sexes in the United States and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Over the last several decades, there have been many advances in both surgical approaches and systemic therapies for the treatment of NSCLC, but the prognosis for advanced disease remains poor. New research, however, is exploring the use of targeted therapies for the treatment of NSCLC. The anaplastic lymphoma kinase (ALK) is involved in normal mammalian central nervous system development. A novel fusion gene involving ALK and the echinoderm microtubule-associated protein-like 4 (EML4) gene has been associated with approximately 5% of NSCLCs and is mutually exclusive of other oncogenic driver mutations. Targeted therapies against this ALK rearrangement are a relatively new treatment modality that aims to improve the prognosis of patients with late-stage disease. Two such drugs have Food and Drug Administration (FDA) approval currently: Crizotinib and Ceritinib. Many other ALK inhibitors are currently being studied in clinical trials as well. The authors aim to provide a comprehensive review of ALK inhibitors for use in NSCLC as well as the future directions and challenges to developing these targeted therapies.
Export Options
About this article
Cite this article as:
David M. Straughan, Sad C. Azoury and Vivek Shukla , Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/1573399811666150615144336
DOI https://dx.doi.org/10.2174/1573399811666150615144336 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets Meet Our Regional Editor
Current Gene Therapy Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Salivary Antioxidants and Oxidative Stress Markers in Male Smokers
Combinatorial Chemistry & High Throughput Screening Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy Meet the Editorial Board:
Current Cancer Drug Targets Graphical Abstracts
Letters in Drug Design & Discovery Editorial [Hot Topic: Anti-Lipogenesis as a Novel Strategy for Cancer Therapy (Guest Editors: Jianghua Liu and Deliang Cao)]
Recent Patents on Anti-Cancer Drug Discovery Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Antimetastatic Activities and Mechanisms of Bisdioxopiperazine Compounds
Anti-Cancer Agents in Medicinal Chemistry Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?
Current Gene Therapy Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry